EldahanKC, RabchevskyAG: Autonomic dysreflexia after spinal cord injury: systemic pathophysiology and methods of management. Auton Neurosci, 2018; 209:59–70.
2.
BrowneE, QuinnS, CheyneS, HealyAM: Design and characterisation of an amorphous formulation of nifedipine for the treatment of autonomic dysreflexia. J Pharm Pharmacol, 2021; 73:928–936.
3.
DelhaasEM, FrankemaSPG, HuygenFJPM: Intrathecal baclofen as emergency treatment alleviates severe intractable autonomic dysreflexia in cervical spinal cord injury. J Spinal Cord Med, 2021; 44:617–620.
4.
LiX, RömerG, KerindongoRP, et al.: Sodium Glucose Co-Transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species. Int J Mol Sci, 2021; 22:6044.
KimSR, LeeS-G, KimSH, et al.: SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun, 2020; 11:2127.
7.
KobayashiH, HasegawaY, OnoH: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996; 311:29–35.
8.
SullivanGM, GendreauRM, GendreauJ, et al.: Randomized clinical trial of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related PTSD and the role of sleep quality in treatment response. Psychiatry Res, 2021; 301:113974.
9.
KrenzlinH, LorenzV, DanckwardtS, KempskiO, AlessandriB: The importance of thrombin in cerebral injury and disease. Int J Mol Sci, 2016; 17:84.
10.
AraiT, MiklossyJ, KlegerisA, GuoJP, McGeerPL: Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol, 2006; 65:19–25.
11.
GrammasP, SamanyPG, ThirumangalakudiL: Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis, 2006; 9:51–58.
12.
KandilEA, SayedRH, AhmedLA, Abd El FattahMA, El-SayehBM: Modulatory Role of Nurr1 activation and thrombin inhibition in the neuroprotective effects of dabigatran etexilate in rotenone-induced parkinson's disease in rats. Mol Neurobiol, 2018; 55:4078–4089.
13.
ZulfiqarZ, ShahFA, ShafiqueS, et al.: Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats. J Inflamm Res, 2020; 13:1185–1205.
14.
OridateN, TakedaH, AsakaM, et al.: Acid-suppression therapy offers varied laryngopharyngeal and esophageal symptom relief in laryngopharyngeal reflux patients. Dig Dis Sci, 2008; 53:2033–2038.
15.
StewardDL, WilsonKM, KellyDH, et al.: Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg, 2004; 131:342–350.
16.
LiY, XuG, ZhouB, et al.: Effects of acids, pepsin, bile acids, and trypsin on laryngopharyngeal reflux diseases: physiopathology and therapeutic targets. Eur Arch Otorhinolaryngol, 2021. [Epub ahead of print]; DOI: 10.1007/s00405-021-07201-w
17.
SamuelsTL, JohnstonN: Pepsin in gastroesophageal and extraesophageal reflux: molecular pathophysiology and diagnostic utility. Curr Opin Otolaryngol Head Neck Surg, 2020; 28:401–409.
18.
BruzzoneA, PiñeroCP, RojasP, et al.: alpha(2)-Adrenoceptors enhance cell proliferation and mammary tumor growth acting through both the stroma and the tumor cells. Curr Cancer Drug Targets, 2011; 11:763–774.
19.
BruzzoneA, Pérez PiñeroC, CastilloLF, et al.: Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol, 2008; 155:494–504.
20.
ShenS-G, ZhangD, HuH-T, LiJ-H, WangZ, MaQ-Y: Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro. World J Gastroenterol, 2008; 14:2358–2363.
21.
KannoN, LesageG, PhinizyJL, GlaserS, FrancisH, AlpiniG: Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology, 2002; 35:1329–1340.
22.
GudbergsenH, OvergaardA, HenriksenM, et al.: Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr, 2021; 113:314–323.
23.
TonneijckL, MuskietMHA, SmitsMM, et al.: Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: post-hoc analyses of four clinical trials. Diabetes Obes Metab, 2018; 20:1235–1245.
24.
DobleA: The pharmacology and mechanism of action of riluzole. Neurology, 1996; 47(6Suppl 4):S233–S241.
25.
SinghNS, RutkowskaE, PlazinskaA, et al.: Ketamine metabolites enantioselectively decrease intracellular D-serine concentrations in PC-12 cells. PLoS One, 2016; 11:e0149499.
26.
ZanosP, MoaddelR, MorrisPJ, et al.: Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev, 2018; 70:621–660.
27.
BellJD: In vogue: ketamine for neuroprotection in acute neurologic injury. Anesth Analg, 2017; 124:1237–1243.
28.
KimMK, LeeSY, ParkHS, et al.: A Randomized, Multicenter, Double-blind, Phase III Study to evaluate the efficacy on allergic rhinitis and safety of a combination therapy of montelukast and levocetirizine in patients with asthma and allergic rhinitis. Clin Ther, 2018; 40:1096–1107.e1.
29.
BhattacharyyaD: Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2. Med Hypotheses, 2020; 144:110046.
30.
KoberF, HeissA, KemingerK, DepischD: [Chemotherapy of highly malignant thyroid tumors]. Wien Klin Wochenschr, 1990; 102:274–276.
31.
MaoY, LiuJ, ShiT, ChenG, WangS: A Novel Self-Assembly Nanocrystal as Lymph Node-Targeting Delivery System: Higher activity of lymph node targeting and longer efficacy against lymphatic metastasis. AAPS PharmSciTech, 2019; 20:292.
32.
PengL, AgogoGO, GuoJ, YanM: Substance P and fibrotic diseases. Neuropeptides, 2019; 76:101941.
33.
CassidyMR, SheldonHK, GainsburyML, et al.: The neurokinin 1 receptor regulates peritoneal fibrinolytic activity and postoperative adhesion formation. J Surg Res, 2014; 191:12–18.
34.
SmithJ, AllmanD, BadriH, et al.: The Neurokinin-1 receptor antagonist orvepitant is a novel antitussive therapy for chronic refractory cough: results from a phase 2 pilot study (VOLCANO-1). Chest, 2020; 157:111–118.
35.
Mayoral-VaroV, JiménezL, LinkW: The Critical Role of TRIB2 in cancer and therapy resistance. Cancers (Basel), 2021; 13:2701.
36.
MongaJ, AdriantoI, RogersC, et al.: Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. J Biol Chem, 2021; 29:101556.
37.
LiangY, YuD, Perez-SolerR, KlostergaardJ, ZouY: TRIB2 contributes to cisplatin resistance in small cell lung cancer. Oncotarget, 2017; 8:109596–109608.
38.
HoldenBA, FrickeTR, WilsonDA, et al.: Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology, 2016; 123:1036–1042.
39.
SiatkowskiRM, CotterSA, CrockettRS, MillerJM, NovackGD, ZadnikK: Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS, 2008; 12:332–339.
40.
ZarbinMA, JampolLM, JagerRD, et al.: Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology, 2013; 120:1432–1439.
41.
KaraküçükY, GümüşH, EkerS: Evaluation of the effect of fingolimod (FTY720) on macular perfusion by swept-source optical coherence tomography angiography in patients with multiple sclerosis. Cutan Ocul Toxicol, 2020; 39:281–286.
42.
ManadalaS, HajduR, BergstromJ, et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 2002; 296:346–349.
43.
SuiY, NguyenHB, ThaiTQ, IkenakaK, OhnoN: Mitochondrial dynamics in physiology and pathology of myelinated axons. Adv Exp Med Biol, 2019; 1190:145–163.
44.
Ferret-SenaV, CapelaC, SenaA: Metabolic dysfunction and peroxisome proliferator-activated receptors (PPAR) in multiple sclerosis. Int J Mol Sci, 2018; 19:1639.
45.
RackeMK, GockeAR, MuirM, DiabA, DrewPD, Lovett-RackeAE: Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr, 2006; 136:700–703.
46.
Licht-MayerS, CampbellGR, CanizaresM, et al.: Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis. Acta Neuropathol, 2020; 140:143–167.
47.
GommW, von HoltK, ThoméF, et al.: Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol, 2016; 73:410–416.
48.
AhnN, FrenzelS, WittfeldK, BülowR, VölzkeH, LerchMM. Lack of association between proton pump inhibitor use and brain aging: a cross-sectional study. Eur J Clin Pharmacol, 2021; 77:1039–1048.
49.
TaipaleH, TolppanenAM, TiihonenM, TanskanenA, TiihonenJ, HartikainenS: No association between proton pump inhibitor use and risk of Alzheimer's disease. Am J Gastroenterol, 2017; 112:1802–1808.
50.
MirFA, JhaSK: Proton Pump Inhibitor “Lansoprazole” inhibits locus coeruleus's neuronal activity and increases rapid eye movement sleep. ACS Chem Neurosci, 2021; 12:4265–4274.
